Clinical Implications and Prognostic Values of Prostate Cancer Susceptibility Candidate Methylation in Primary Nonmuscle Invasive Bladder Cancer

Table 4

Multivariate Cox regression analysis of disease outcomes according to PRAC methylation in nonmuscle invasive bladder cancer ().

Variables	Recurrence			Progression
	HR	95% CI	value	HR	95% CI	value
Age (<66 yrs versus ≥66 yrs)	0.711	0.364–1.390	0.319	0.884	0.310–2.519	0.817
Sex (male versus female)	1.084	0.441–2.662	0.860	1.148	0.241–5.459	0.862
Number of tumors (single versus multiple)	1.099	0.568–2.127	0.780	1.178	0.420–3.301	0.755
Tumor size (<3 cm versus ≥3 cm)	1.270	0.645–2.499	0.490	4.149	1.184–14.540	0.026
T Stage (Ta versus T1)	0.963	0.437–2.122	0.925	2.028	0.233–17.623	0.521
Grade (G1-2 versus G3)			0.493			0.021
G1	1	—	—	1	—	—
G2	1.124	0.450–2.811	0.803	1.235	0.074–20.544	0.883
G3	1.825	0.567–5.879	0.313	7.280	0.397–133.445	0.181
Intravesical therapy (no versus yes)	1.248	0.610–2.554	0.545	2.061	0.558–7.612	0.558
PRAC (hypomethylation versus hypermethylation)	2.652	1.241–5.667	0.012	9.531	1.172–77.497	0.035

HR: hazard ratio; CI: confidence interval; PRAC: prostate cancer susceptibility candidate.